Toward the development of a system to optimize prescription drug therapy.
作者信息
Kennedy J S
出版信息
Ann N Y Acad Sci. 1981;368:61-6. doi: 10.1111/j.1749-6632.1981.tb15431.x.
Abstract
摘要
相似文献
1
Toward the development of a system to optimize prescription drug therapy.朝着开发一个优化处方药治疗的系统的方向发展。
Ann N Y Acad Sci. 1981;368:61-6. doi: 10.1111/j.1749-6632.1981.tb15431.x.
2
Regulatory differences and similarities: systems in Japan.监管差异与相似之处：日本的体系
Clin Pharmacol Ther. 1976 May;19(5 Pt 2):694-9. doi: 10.1002/cpt1976195part2694.
3
Postmarketing follow-up.
JAMA. 1979 Nov 23;242(21):2310-4.
4
Can postmarketing surveillance help to effect optimal drug therapy?上市后监测能否有助于实现最佳药物治疗？
JAMA. 1979 Nov 30;242(22):2420-2.
5
Drug use data: a different perspective.药物使用数据：一个不同的视角。
JAMA. 1975 Dec 22;234(12):1242-4.
6
Monitoring adverse reactions to drugs: toward a therapeutic audit.药物不良反应监测：迈向治疗性审核
Int J Health Serv. 1974 Winter;4(1):109-23. doi: 10.2190/D2G5-DW5J-F9JH-PHKT.
7
Clinical pharmacology in the United Kingdom.
Clin Pharmacol Ther. 1974 Sep;16(3):605-15. doi: 10.1002/cpt1974163part2605.
8
Present attitudes of governmental drug regulatory agencies.政府药品监管机构目前的态度。
Int J Clin Pharmacol. 1973 Apr;7(2):168-77.
9
Toward Better-Quality Compounded Drugs - An Update from the FDA.迈向更高质量的复方制剂——来自美国食品药品监督管理局的最新消息
N Engl J Med. 2017 Dec 28;377(26):2509-2512. doi: 10.1056/NEJMp1712905.
10
Minimum acceptable requirements for introduction and marketing of drugs.
Drugs. 1974;7(6):409-13. doi: 10.2165/00003495-197407060-00001.
Zotero 插件